CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to MRK

pembrolizumab

Phase 3
MERCK (MRK)

Phase 3

Development Phase

19

Upcoming Catalysts

1

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Nov '27
MRKPhase 2

Pembrolizumab Phase 2 Est. Readout

pembrolizumab
Nov 2027~
CT.gov
00%
Q4 '27
MRKPhase 3

Pembrolizumab Phase 3 Est. Readout

pembrolizumab
Q4 2027~Q
CT.gov
00%
Q4 '27
MRKPhase 2

pembrolizumab Phase 2 Est. Readout

pembrolizumab
Q4 2027~Q
CT.gov
00%
Q4 '27
MRKPhase 2

Pembrolizumab Phase 2 Est. Readout

pembrolizumab
Q4 2027~Q
CT.gov
00%
Q3 '27
MRKPhase 2

Pembrolizumab Phase 2 Est. Readout

pembrolizumab
Q3 2027~Q
CT.gov
00%
Q3 '27
MRKPhase 2

Pembrolizumab Phase 2 Est. Readout

pembrolizumab
Q3 2027~Q
CT.gov
00%
Jul '27
MRKPhase 2

Pembrolizumab Phase 2 Est. Readout

pembrolizumab
Jul 2027~
CT.gov
00%
Q3 '27
MRKPhase 3

Pembrolizumab Phase 3 Est. Readout (PROLoNg)

pembrolizumab
Q3 2027~Q
CT.gov
00%
Jun '27
MRKPhase 2

Pembrolizumab Phase 2 Est. Readout

pembrolizumab
Jun 2027~
CT.gov
00%
Q2 '27
MRKPhase 3

pembrolizumab Phase 3 Est. Readout

pembrolizumab
Q2 2027~Q
CT.gov
00%
Apr '27
MRKPhase 2

Pembrolizumab Phase 2 Est. Readout

pembrolizumab
Apr 2027~
CT.gov
00%
Feb '27
MRKPhase 2

pembrolizumab Phase 2 Est. Readout

pembrolizumab
Feb 2027~
CT.gov
00%
Jan '27
MRKPhase 3
✗Negative

Pembrolizumab Phase 3 Est. Readout

pembrolizumab
Jan 2027~
CT.gov
Jan '27
MRKPhase 2

Pembrolizumab Phase 2 Est. Readout

pembrolizumab
Jan 2027~
CT.gov
00%
Jan '27
MRKPhase 2

Pembrolizumab Phase 2 Est. Readout

pembrolizumab
Jan 2027~
CT.gov
00%
Jan '27
MRKPhase 3
✓Positive

Pembrolizumab Phase 3 Est. Readout

pembrolizumab
Jan 2027~
CT.gov
Dec '26
MRKPhase 2

Pembrolizumab Phase 2 Est. Readout

pembrolizumab
Dec 2026~
CT.gov
00%
Dec '26
MRKPhase 2

pembrolizumab Phase 2 Est. Readout

pembrolizumab
Dec 2026~
CT.gov
00%
Dec '26
MRKPhase 2

Pembrolizumab Phase 2 Est. Readout

pembrolizumab
Dec 2026~
CT.gov
00%
Development History
Oct '26
MRKPhase 2

Pembrolizumab Phase 2 Est. Readout

pembrolizumab
Oct 2026~
CT.gov
00%
Competitive Landscape

1 competitor in Colorectal Neoplasms

View Full Landscape
Drug Information

Target Indication

Colorectal Neoplasms

Clinical Trial

NCT03485209

Last updated: 8/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.